Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07210632 · ClinicalTrials.gov registry record · Early Phase 1
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
A Early Phase 1 study, sponsored by Eben Rosenthal.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 38
- Enrollment target
NCT07210632 is a Early Phase 1 study that is actively recruiting participants, run by Eben Rosenthal. The registered enrollment target is 38 participants.
The verdict
NCT07210632, a Early Phase 1 study, is actively recruiting participants, sponsored by Eben Rosenthal.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patient population. This clinical trial investigates a novel imaging-enabled formulation of nivolumab-IRDye800 (nivo800) which incorporates a near-infrared (NIR) fluorescent dye to enable real-time visualization of drug distribution within tumor tissue.
Interventions
- DRUG Nivolumab
- DRUG Nivolumab-IRDye800
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2026-03-27 |
| Est. Completion | 2031-03-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07210632
The ClinicalTrials.gov registry entry for NCT07210632 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eben Rosenthal, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT07210632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07210632 about?
NCT07210632 is a clinical study titled "Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)". High-grade gliomas (HGGs) are among the most aggressive and treatment-resistant brain tumors. Immunotherapy with checkpoint inhibitors like nivolumab has shown promise, but its efficacy remains variable and poorly understood in this patient population. This clinical trial investigates a novel imagin...
What is the current status of trial NCT07210632?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 38 participants. The study started on 2026-03-27. Estimated completion is 2031-03-30.
What interventions are being tested in trial NCT07210632?
The interventions under investigation include: Nivolumab (DRUG), Nivolumab-IRDye800 (DRUG).
Who is sponsoring clinical trial NCT07210632?
This trial is sponsored by Eben Rosenthal, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.